Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Read More
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodAcute Lymphoblastic Leukemia | November 23, 2022
Nicholas J. Short, MD, speaks about how novel chemotherapy can eliminate the need for transplant in ALL.
Leah LawrencePrint | November 23, 2022
A deeper understanding of ALL has led to more targeted approaches and personalized treatments for this patient population.
Leah SherwoodAcute Lymphoblastic Leukemia | November 21, 2022
A UK regulator granted an Innovation Passport to ALETA-001 for patients with non-Hodgkin lymphoma and ALL.
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Leah SherwoodAcute Lymphoblastic Leukemia | November 2, 2022
CRISPR/Cas9 technology was used to engineer donor T cells to treat children with pediatric B-ALL.
Leah SherwoodAcute Lymphoblastic Leukemia | November 2, 2022
Frontline sequential chemotherapy with blinatumomab resulted in encouraging long-term survival in B-cell ALL.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 30, 2022
Blood Cancers Today Associate Editor Elias Jabbour, MD, gave his thoughts on the first day of the 2022 SOHO Annual Meeting.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 28, 2022
The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 19, 2022
September is Blood Cancer Awareness Month.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 13, 2022
Aaron Logan, MD, PhD, and Elias Jabbour, MD, discussed whether MRD negativity indicates a cure in patients with AML.
Leah SherwoodAcute Lymphoblastic Leukemia | August 10, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has issued...
Cecilia BrownPrint | August 8, 2022
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Leah SherwoodAcute Lymphoblastic Leukemia | August 8, 2022
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Leah SherwoodTransplantation & Cellular Therapy | August 4, 2022
Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.
Leah SherwoodTransplantation & Cellular Therapy | August 2, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation and Rare Pediatric...
Leah SherwoodTransplantation & Cellular Therapy | July 29, 2022
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Leah SherwoodAcute Lymphoblastic Leukemia | July 15, 2022
A new study found that more than one-third of patients aged older than 65 years do not receive...
Leah SherwoodAcute Lymphoblastic Leukemia | June 29, 2022
Treatment produced an overall response rate of 87.5% in those with BM disease and a 85.4% remission rate in those with CNSL.
Advertisement
Editorial Board

Advertisement